Ink dries on Hologic's deal to buy Mobidiag

By staff writers

Hologic announced the completion of its $808 million acquisition of biotechnology company Mobidiag. The Finnish-French company develops near-patient, acute-care molecular diagnostic testing products.

Mobidiag's product line includes molecular diagnostic instruments and tests for acute care conditions, including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections, according to a release.

The acquisition was first announced in April this year.

Copyright © 2021

To read this and get access to all of the exclusive content on, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?